E
Eppie M. Yiu
Researcher at Royal Children's Hospital
Publications - 67
Citations - 2287
Eppie M. Yiu is an academic researcher from Royal Children's Hospital. The author has contributed to research in topics: Ataxia & Frataxin. The author has an hindex of 23, co-authored 62 publications receiving 1609 citations. Previous affiliations of Eppie M. Yiu include University of Melbourne.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of Guillain–Barré syndrome in ten steps
Sonja E. Leonhard,Melissa R. Mandarakas,Francisco de Assis Aquino Gondim,Kathleen Bateman,Maria Lucia Brito Ferreira,David R. Cornblath,Pieter A. van Doorn,Mario Emilio Dourado,Richard A. C. Hughes,Badrul Islam,Susumu Kusunoki,Carlos A. Pardo,Ricardo Reisin,James J. Sejvar,Nortina Shahrizaila,Cristiane Soares,Thirugnanam Umapathi,Yuzhong Wang,Eppie M. Yiu,Eppie M. Yiu,Hugh J. Willison,Bart C. Jacobs +21 more
TL;DR: A globally applicable guideline for the diagnosis and management of Guillain–Barré syndrome is provided, including information on early recognition of the disease, prediction of clinical course and outcome, andmanagement of complications and sequelae.
Journal ArticleDOI
Duchenne muscular dystrophy
TL;DR: The use of corticosteroids, non‐invasive respiratory support, and active surveillance and management of associated complications have improved ambulation, function, quality of life and life expectancy in Duchenne muscular dystrophy.
Journal ArticleDOI
Ascorbic acid for Charcot–Marie–Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial
Joshua Burns,Robert A. Ouvrier,Eppie M. Yiu,Pathma D. Joseph,Andrew J. Kornberg,Michael C Fahey,Monique M. Ryan +6 more
TL;DR: 12 months of treatment with high-dose ascorbic acid was safe and well tolerated but none of the expected efficacy endpoints were reached and there was no measurable effect of ascorBic acid on neurophysiological, strength, function, or quality of life outcomes.
Journal ArticleDOI
Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia.
Charles A. Galea,Aamira Huq,Paul J. Lockhart,Geneieve Tai,Louise A. Corben,Louise A. Corben,Eppie M. Yiu,Eppie M. Yiu,Lyle C. Gurrin,David A. Lynch,Sarah Gelbard,Alexandra Durr,Françoise Pousset,Michael H Parkinson,Robyn Labrum,Paola Giunti,Paola Giunti,Susan Perlman,Martin B. Delatycki,Marguerite V. Evans-Galea +19 more
TL;DR: This work examined disease‐causing mutations and the impact on frataxin structure/function and clinical outcome in FRDA.
Journal ArticleDOI
Progression of Friedreich ataxia: quantitative characterization over 5 years.
Maya Patel,Charles J. Isaacs,Lauren Seyer,Karlla W. Brigatti,Sarah Gelbard,Cassandra J Strawser,Debbie L. Foerster,Julianna E. Shinnick,Kimberly Schadt,Eppie M. Yiu,Martin B. Delatycki,Susan Perlman,George Wilmot,Theresa A. Zesiewicz,Katherine D. Mathews,Christopher M. Gomez,Grace Yoon,S. H. Subramony,Alicia Brocht,Jennifer Farmer,David A. Lynch +20 more
TL;DR: This study analyzed neurological outcomes and changes to identify predictors of progression and generate power calculations for clinical trials in Friedreich ataxia.